**5. Conclusion**

The global incidence rate for OC is expected to increase by 47% by 2040 [141]. Except for the emergence of PARP inhibitors in women with HRD HGSOC tumors, the conventional treatment protocol for other OC subtypes has remained the same since the 1980s, with no significant impact on survival rates. Screening for highgrade OCs remains a challenge. With the advances in the high throughput screening technologies, the focus is warranted to shift towards translational research to treat each OC subtype for their underlying genomic aberrations.
